The FDA approved Novo Nordisk’s oral semaglutide formulation of Wegovy, marking the first FDA‑cleared oral GLP‑1 indicated for weight loss in adults. Clinical trial data showed substantial mean weight reductions at one year, and Novo Nordisk expects a market launch in early January. Separately, CMS signaled a threshold event by planning a voluntary model to enable Medicare Part D plans and state Medicaid programs to cover GLP‑1 drugs for weight management, a step that could materially expand payer access to these therapies.